Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Nippon Shinyaku Licenses Leukemia Drug Marketing Rights In Korea To Korean Company

This article was originally published in PharmAsia News

Executive Summary

Nippon Shinyaku signed a license agreement Dec. 4 with Korean drug seller BL&H and provided the company exclusive marketing rights to acute promyelocytic leukemia drug Trisenox (arsenic trioxide) in South Korea. Nippon Shinyaku obtained the manufacturing and marketing rights in Japan and Korea from U.S. drug maker Cephalon in 2002, and started manufacturing and marketing it in Japan in 2004, but the company has not marketed the drug in South Korea. Payment details were not disclosed. BL&H plans to market the drug in spring 2010. (Click here for more - Japanese language

Table

View full table

Tags:
Latest Headlines

Supply Chain Derisking: The Case For US-India Partnering Amid China Clout

BridgeBio Spins Out Cancer Arm With $200m Fundraise

Emergex Goes To Battle Against ‘The Nasties’

Finance Watch: Venture Rounds Trend Toward The High End

See All
UsernamePublicRestriction

Register

SC067394

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By